ACC Scientific Session - American College of Cardiology Scientific Session

Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.

Small case report found an association between the Zika virus and cardiovascular complications.

FOURIER trial meets its primary composite endpoint reducing cardiovascular risk factors.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.